ArticleMedicine2026
Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the 10-year outcomes and efficacy of intravitreal injection (IVI) of ranibizumab for treatment of myopic choroidal neovascularization (CNV). This retrospective study included 12 consecutive eyes with myopic CNV treated with ranibizumab with a minimum follow-up of 10 years. The primary outcome was the mean change in best corrected visual acuity (BCVA). The secondary outcomes were Snellen line visual acuity distribution, number of IVIs, and changes in areas of chorioretinal patchy atrophy. The mean number of IVIs was 4.92 ± 5.93 (range, 1-23). The mean BCVA at baseline was 0.49 ± 0.54 logMAR; it improved to 0.29 ± 0.38(P = .017), 0.40 ± 0.39(P = .186), 0.32 ± 0.41 (P = .087), 0.49 ± 0.40 (P = .643), 0.45 ± 0.51 (P = .817) logMAR at 1, 3, 5, 6, and 10 years, respectively. At baseline and 10 years, 8.3% of eyes had a BCVA of 6/60 or worse, and 58.33% and 50% of eyes had a BCVA of 6/12 or better, respectively. The 3-month loading protocol was significantly associated with a Snellen visual acuity gain of >3 lines at 5 years (P = .035); however, the association was lost at 10 years (P = .371). Patchy atrophy increased in 5 eyes (41.67%) after 10 years. Intravitreal ranibizumab injections provided favorable and safe 10-year visual outcomes for myopic CNV. These results are notably superior to the 10-year natural history previously reported in Japanese patients, suggesting that long-term anti-VEGF therapy can effectively preserve vision in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.